JSH-23 nmr Effect of revised assumptions for US-FRAX The results of these revisions
are summarized in Table 6, which compares the current rates used in US-FRAX (based on the sum of the four individual fracture types from Olmsted County) to the newly derived four-fracture rates based on the steps described above. The revised base annual four-fracture rates are lower, and this should result in lower US-FRAX 10-year four-fracture probability estimates. Indeed, an average one-third reduction in four-fracture risk can be expected in both women and men of all ages. Table 6 Comparison of ratios of 10-year 4 fracture probability NCT-501 to 10-year hip fracture probability alone obtained from current FRAX® (available on web site, January 2009) Country Age, years 50 55 60 65 70 75 80 Estimates from FRAX®a (10-year risk) US currentb 16 13 11 11 6.2 4.2 3.5 Sweden 11 9.0 6.3 4.8 3.3 2.4 2.1 UK 18 12 8.6 6.6 4.8 3.1 2.4 Italy 16 9.0 6.7 5.1 3.3 2.4 2.1 France 12 9.3 6.6 5.1 3.5 2.5 2.3 Spain 14 10 6.0 4.6 3.5 TSA HDAC purchase 2.5 2.3 Based on proposed revision to
US incidence rates (annual) US revised 14 12 10 5.9 4.4 2.4 1.9 The table also compares the current US ratios with estimates of ratios that might be expected based on revised annual US incidence rates aFrom FRAX® tables for white women, without BMD, BMI = 25, and no risk factors bCalculated from the October 2008 version of US FRAX, for white women, without BMD, BMI = 25, and no risk factors This revision of the US-FRAX incidence rates should also mean that the absolute likelihood of four fractures for US non-Hispanic white women will be closer to the percentages obtained using FRAX® for European countries. This was evaluated by comparing the four-fracture/hip
fracture ratios (for 10-year probability) from these countries to the ratio of annual risk of these categories of fractures in the proposed revision. Thus, Table 6 also shows the 10-year four-fracture/hip fracture ratio for different ages calculated from FRAX® online tables for a woman with body mass index (BMI) of 25, without clinical risk factors, and with no BMD value. The ratios across Europe are quite similar, while the US ratios based on Rucaparib concentration the October 2008 US-FRAX tool are considerably higher. Judging from our revised annual four-fracture and hip fracture incidence rates, it is likely that the revised US-FRAX will provide results more consistent with those of other countries. Discussion Since FRAX® was adapted for application in the USA some years ago, newer and more robust fracture incidence and mortality rates have become available. In particular, we feel it highly advantageous to use recent hip fracture incidence rates, which have the further advantage of being based on more robust national data.